肝硬化心肌病发病机制与临床相关性研究现况

摘要/Abstract

摘要： 肝硬化心肌病(cirrhotic cardiomyopathy ,CCM)是排除基础心脏疾病之后,在肝硬化患者中出现的心脏舒张、收缩功能受损及电生理异常的慢性心脏功能障碍。患者因症状隐匿且常规检查的局限性而不易被临床关注。本文就近年来对CCM发病机制、诊断标准及临床相关性的研究现状及进展进行综述,以期提高临床医生对CCM的认识水平。

关键词: 肝硬化, 心脏功能障碍, 肝移植, 非选择性β受体阻滞剂

陈欣, 陈琳. 肝硬化心肌病发病机制与临床相关性研究现况[J]. 肝脏, 2023, 28(1): 121-124.

[1] Yoon KT, Liu H, Lee SS. Cirrhotic cardiomyopathy. Curr Gastroenterol Rep, 2020, 22(9): 45.
[2] Zardi EM, Abbate A, Zardi DM, et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol, 2010, 56(7): 539-549.
[3] Siniscalchi A, Aurini L, Spedicato S, et al. Hyperdynamic circulation in cirrhosis: predictive factors and outcome following liver transplantation. Minerva Anestesiol, 2013, 79(1): 15-23.
[4] Gunarathne L S, Rajapaksha H, Shackel N, et al. Cirrhotic portal hypertension: From pathophysiology to novel therapeutics. World J Gastroenterol, 2020, 26(40): 6111-6140.
[5] Moller S, Lee S S. Cirrhotic cardiomyopathy. J Hepatol, 2018, 69(4): 958-960.
[6] Fukui H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World J Hepatol, 2015, 7(3): 425-442.
[7] Gregolin CS, do Nascimento M, Borges de Souza S L, et al. Myocardial dysfunction in cirrhotic cardiomyopathy is associated with alterations of phospholamban phosphorylation and il-6 levels. Arch Med Res, 2021, 52(3): 284-293.
[8] Gazawi H, Ljubuncic P, Cogan U, et al. The effects of bile acids on beta-adrenoceptors, fluidity, and the extent of lipid peroxidation in rat cardiac membranes. Biochem Pharmacol, 2000, 59(12): 1623-1628.
[9] Voiosu A, Wiese S, Voiosu T, et al. Bile acids and cardiovascular function in cirrhosis. Liver Int, 2017, 37(10): 1420-1430.
[10] Møller S, Hove JD, Dixen U, et al. New insights into cirrhotic cardiomyopathy. Int J Cardiol, 2013, 167(4): 1101-1108.
[11] Yu S, Sun L, Wang H, et al. Autonomic regulation of imbalance-induced myocardial fibrosis and its mechanism in rats with cirrhosis. Exp Ther Med, 2021, 22(3): 1040.
[12] Ma L, Liu X, Wu Q, et al. Role of Anti-Beta-1-Adrenergic receptor antibodies in cardiac dysfunction in patients with cirrhotic cardiomyopathy. J Cardiovasc Transl Res, 2021.
[13] Ligresti A, De Petrocellis L, Di Marzo V. From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol Rev, 2016, 96(4): 1593-1659.
[14] Tam J, Liu J, Mukhopadhyay B, et al. Endocannabinoids in liver disease. Hepatology, 2011, 53(1): 346-355.
[15] Pacher P, Steffens S, Hasko G, et al. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol, 2018, 15(3): 151-166.
[16] Jouanjus E, Lapeyre-Mestre M, Micallef J, et al. Cannabis use: signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc, 2014, 3(2): e000638.
[17] Cakir M, Tekin S, Okan A, et al. The ameliorating effect of cannabinoid type 2 receptor activation on brain, lung, liver and heart damage in cecal ligation and puncture-induced sepsis model in rats. Int Immunopharmacol, 2020, 78: 105978.
[18] Louvet A, Teixeira-Clerc F, Chobert M N, et al. Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology, 2011, 54(4): 1217-1226.
[19] Matyas C, Erdelyi K, Trojnar E, et al. Interplay of Liver-Heart inflammatory axis and cannabinoid 2 receptor signaling in an experimental model of hepatic cardiomyopathy. Hepatology, 2020, 71(4): 1391-1407.
[20] Glenn TK, Honar H, Liu H, et al. Role of cardiac myofilament proteins titin and collagen in the pathogenesis of diastolic dysfunction in cirrhotic rats. J Hepatol, 2011, 55(6): 1249-1255.
[21] Lee SS. Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy?. Hepatology (Baltimore, Md), 2003, 38(5): 1089-1091.
[22] Wiese S, Hove J, Mo S, et al. Myocardial extracellular volume quantified by magnetic resonance is increased in cirrhosis and related to poor outcome. Liver Int, 2018, 38(9): 1614-1623.
[23] Wiese S, Voiosu A, Hove J D, et al. Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy. Aliment Pharmacol Ther, 2020, 52(2): 340-350.
[24] Honar H, Liu H, Zhang M L, et al. Impaired myosin isoform shift and calcium transients contribute to cellular pathogenesis of rat cirrhotic cardiomyopathy. Liver Int, 2020, 40(11): 2808-2819.
[25] Joseph LC, Reyes MV, Lakkadi KR, et al. PKCδ causes sepsis-induced cardiomyopathy by inducing mitochondrial dysfunction. Am J Physiol Heart Circ Physiol, 2020, 318(4): H778-H786.
[26] Wu H, Liu J, Li W, et al. LncRNA-HOTAIR promotes TNF-alpha production in cardiomyocytes of LPS-induced sepsis mice by activating NF-kappaB pathway. Biochem Biophys Res Commun, 2016, 471(1): 240-246.
[27] Izzy M, VanWagner LB, Lin G, et al. Redefining Cirrhotic Cardiomyopathy for the Modern Era. Hepatology (Baltimore, Md), 2020, 71(1): 334-345.
[28] Lauridsen TK, Alhede C, Crowley AL, et al. Two-dimensional global longitudinal strain is superior to left ventricular ejection fraction in prediction of outcome in patients with left-sided infective endocarditis. Int J Cardiol, 2018, 260: 118-123.
[29] Izzy MJ, VanWagner LB. Current concepts of cirrhotic cardiomyopathy. Clin Liver Dis, 2021, 25(2): 471-481.
[30] Izzy M, Soldatova A, Sun X, et al. Cirrhotic cardiomyopathy predicts posttransplant cardiovascular disease: revelations of the new diagnostic criteria. Liver Transpl, 2021, 27(6): 876-886.
[31] Mechelinck M, Hartmann B, Hamada S, et al. Global longitudinal strain at rest as an independent predictor of mortality in liver transplant candidates: a retrospective clinical study. J Clin Med, 2020, 9(8).
[32] Billey C, Billet S, Robic MA, et al. A prospective study identifying predictive factors of cardiac decompensation after transjugular intrahepatic portosystemic shunt: the toulouse algorithm. Hepatology, 2019, 70(6): 1928-1941.
[33] 汪菁峰,马婧嶔,罗剑钧.肝硬化患者经颈静脉肝内门体分流术对血流动力学的影响.中华内科杂志,2020,59(09):700-705.
[34] Alvarado-Tapias E, Ardevol A, Garcia-Guix M, et al. Short-term hemodynamic effects of beta-blockers influence survival of patients with decompensated cirrhosis. J Hepatol, 2020, 73(4): 829-841.

肝硬化心肌病发病机制与临床相关性研究现况

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	翟庆慧, 刘婉姝, 田华, 李东泽, 辛绍杰. 肝硬化及并发症对慢加急性肝衰竭预后的影响[J]. 肝脏, 2023, 28(1): 37-40.
[2]	郭贺冰, 王雪梅, 刘景院. 放腹水对肝硬化患者腹腔内压及肾脏血流灌注的影响[J]. 肝脏, 2023, 28(1): 50-54.
[3]	何青莲, 余保平, 肖勇. 肝硬化食管胃静脉曲张出血患者内镜治疗后再出血的危险因素分析[J]. 肝脏, 2023, 28(1): 55-60.
[4]	石红, 薛小春, 王德琴, 吕忠美. 血清LPO、APN和TGF-β1水平检测对酒精性肝硬化患者病情严重程度和预后评估的价值[J]. 肝脏, 2023, 28(1): 70-74.
[5]	章正兰, 莫瑞东, 姜绍文, 谢青. 非选择性β受体阻滞剂预防静脉曲张出血及再出血[J]. 肝脏, 2023, 28(1): 117-120.
[6]	张丽丽, 胡建华, 汪九重, 李斐然, 王保华. 酒精相关性慢性肝衰竭患者临床特点分析[J]. 肝脏, 2022, 27(9): 963-965.
[7]	慕之勇, 刘钰懿, 王军, 陈东风, 文良志. 肝硬化患者经颈静脉肝内门体分流术与肝细胞癌发生相关性的meta分析[J]. 肝脏, 2022, 27(9): 978-982.
[8]	胡维杰, 陈小萍, 吴荣刚, 马臻雏. T2WI序列图像纹理分析对肝硬化浸润性肝癌和局灶性融合性纤维化的鉴别诊断价值[J]. 肝脏, 2022, 27(9): 986-989.
[9]	高政聪, 雷作汉, 郭舜琴. 低血红蛋白/红细胞分布宽度比值对HBV相关失代偿期肝硬化预后的评价[J]. 肝脏, 2022, 27(9): 1004-1007.
[10]	朱雪晶, 王梦婷, 鄢和新, 黄仁杰. 慢性肝病常用动物模型及建模方案[J]. 肝脏, 2022, 27(9): 1030-1035.
[11]	谢巧华, 王巍, 唐龙, 陈佳霖, 苏妙芳, 蔡奇志. 急性肾损伤对失代偿期乙型肝炎肝硬化患者临床预后的影响[J]. 肝脏, 2022, 27(8): 868-870.
[12]	佟印妮, 郑吉敏, 韩丹, 江萍, 王存凯, 王玉珍, 白云. 986例肝硬化患者病因及临床特点分析[J]. 肝脏, 2022, 27(8): 871-873.
[13]	王利慧, 王荣希, 赵泽源, 郭振凯. 失代偿期乙型肝炎肝硬化患者门静脉血栓形成的临床意义[J]. 肝脏, 2022, 27(8): 874-876.
[14]	姚朝光, 蓝婧, 黄理, 陈丽芬, 覃冬林, 黄洁婕, 黄佳. 乙型肝炎肝硬化伴肺部感染患者分离株菌种及药敏分析[J]. 肝脏, 2022, 27(8): 881-883.
[15]	谢慧, 王亮亮, 江凯, 袁潇. 多层螺旋CT与高场强磁共振LAVA增强对乙型肝炎肝硬化背景小肝癌的诊断价值对比[J]. 肝脏, 2022, 27(8): 895-897.